Pay in 4 interest-free payments of $5.24 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
These findings have led experts to consider these medications as protective therapies rather than purely glucose-lowering drugs
These medications are designed to act on pathways associated with the GLP-1 hormone, which is naturally released in the gastrointestinal tract after eating
One such investigation, known as the SUSTAIN-6 trial, was a moderate-sized trial that examined use of the once-weekly injectable agent semaglutide on cardiovascular outcomes when compared with placebo
Check out the Florida Health Care disclosures for more info
Researchers independently took up investigating the association between GLP-1s and GI side effects, especially gastroparesis, in three separate studies presented this week
